Effects of duloxetine on painful physical symptoms associated with depression

Harvard University, Cambridge, Massachusetts, United States
Psychosomatics (Impact Factor: 1.67). 03/2004; 45(1):17-28. DOI: 10.1176/appi.psy.45.1.17
Source: PubMed

ABSTRACT Painful physical symptoms are common features of major depressive disorder and may be the presenting complaints in primary care settings. The effect of the dual serotonin (5-HT) and norepinephrine reuptake inhibitor duloxetine on emotional and painful physical symptoms in outpatients with major depressive disorder was evaluated in three randomized, double-blind, placebo-controlled trials. The trials' primary objective was to evaluate the effect of duloxetine on mood, and subjects were not enrolled on the basis of presence, type, or severity of pain. However, the pain-relieving effects of duloxetine were evaluated by a priori defined analyses of results from a visual analogue scale and the Somatic Symptom Inventory. Compared with placebo, duloxetine was associated with significant reduction in pain severity. The authors concluded that duloxetine reduces the painful physical symptoms of depression.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Los pacientes con trastornos depresivos frecuentemente manifiestan quejas somáticas como, por ejemplo, dolor. La mejoría en la percepción del dolor que se produce en pacientes con síntomas depresivos tratados con antidepresivos puede deberse a una mejoría en la depresión. Varias publicaciones indican que la actividad antinociceptiva de los antidepresivos es independiente de la mejoría del estado de ánimo y que está en relación con el efecto de estos fármacos en vías noradrenérgicas y serotoninérgicas ascendentes y descendentes.En modelos animales, sustancias que inhiben selectivamente la recaptación de noradrenalina disminuyen la percepción del dolor; compuestos que inhiben de manera selectiva la recaptación de serotonina no tienen ese efecto pero potencian el efecto antinociceptivo de las que inhiben la recaptación de noradrenalina.Disminuyendo la percepción del dolor se contribuye a mejorar los síntomas depresivos que pudieran coexistir. Una mejoría en los síntomas depresivos que pudieran magnificar la percepción del dolor contribuiría a disminuir esta última; el efecto de algunos fármacos en el sistema límbico puede conducir a mejorar tanto la percepción del dolor como el estado de ánimo.Duloxetina posee acción dual como inhibidor de la recaptación de serotonina y noradrenalina. Investigaciones recientes señalan que no es possible discernir entre el efecto analgésico y antidepresivo de duloxetina. Otros estudios evidencian que el efecto de duloxetina en la percepción del dolor es independiente del efecto antidepresivo. La evolución del caso presentado parece apoyar la hipótesis de que duloxetina contribuye de manera independiente a la mejoría de ambos tipos de síntomas.
    01/2008; 15(1):23-26. DOI:10.1016/S1134-5934(08)71117-5
  • [Show abstract] [Hide abstract]
    ABSTRACT: Painful diabetic peripheral neuropathy (DPN) is a common complication of diabetes mellitus, affecting, by some estimates, up to one quarter of diabetic patients. Since 2010, no fewer than 5 major international treatment guidelines for painful DPN have been issued, and there are meaningful differences among them. Duloxetine, pregabalin, gabapentin, and tricyclic antidepressants are the mainstays of treatment, but the choice of which class or agent to use in any given patient should be informed by patient characteristics. This review seeks to describe the differences among the recently issued guidelines, to assess the evidence on which they are based, and to offer insight into the most appropriate treatment choices based on patient characteristics.
    Journal of Diabetes and its Complications 08/2014; 29(1). DOI:10.1016/j.jdiacomp.2014.08.008 · 1.93 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Unexplained painful physical symptoms are commonly reported by depressed patients. The evidence suggests that dual-action antidepressants are potent in relieving pain in depression. However, a direct comparison of the effects of selective serotonergic and selective noradrenergic antidepressants on painful symptoms has not been investigated so far. Sixty patients who participated in the Genome-based Therapeutic Drugs for Depression study with a diagnosis of moderate or severe episodes of depression according to the International Classification of Diseases, 10th Revision, and the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, criteria were involved. All the participants were randomly allocated to receive nortriptyline or escitalopram. The severity of depression was measured using the Montgomery-Åsberg Depression Rating Scale, the Hamilton Depression Rating Scale and the Beck Depression Inventory at weeks 0, 2, 4, 6 and 8. The intensity of pain was measured on the Visual Analog Scale at the same points of the study. At "week 0," 83.3% of the patients later randomized to treatment with escitalopram and 86.7% of those treated with nortriptyline reported at least one painful symptom. A significant decrease of pain intensity was observed after 2 weeks of treatment. The two groups did not differ in degree of pain reduction at weeks 2, 4, 6 and 8 in comparison to baseline values. A 50% reduction in pain intensity preceded the 50% reduction of depression severity. The intensity of pain at "week 0" did not differ in remitted or nonremitted patients at week 8. Both selective serotonergic and selective noradrenergic antidepressants are equally effective in alleviations of painful physical symptoms of depression. The presence of painful symptoms before the onset of treatment did not determine the final response. Copyright © 2014 Elsevier Inc. All rights reserved.
    General Hospital Psychiatry 10/2014; 37(1). DOI:10.1016/j.genhosppsych.2014.10.005 · 2.90 Impact Factor